| scholarly article | Q13442814 |
| review article | Q7318358 |
| P6179 | Dimensions Publication ID | 1039743692 |
| P356 | DOI | 10.1186/1756-8722-6-66 |
| P932 | PMC publication ID | 3844370 |
| P698 | PubMed publication ID | 24010946 |
| P5875 | ResearchGate publication ID | 256466711 |
| P2093 | author name string | Amikar Sehdev | |
| Daniel V T Catenacci | |||
| P2860 | cites work | Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction | Q28215716 |
| Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine | Q28255790 | ||
| Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer | Q29619394 | ||
| Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma | Q32033905 | ||
| Surgical outcome after docetaxel-based neoadjuvant chemotherapy in locally-advanced gastric cancer | Q33672879 | ||
| Sequential FDG-PET and induction chemotherapy in locally advanced adenocarcinoma of the Oesophago-gastric junction (AEG): the Heidelberg Imaging program in Cancer of the oesophago-gastric junction during Neoadjuvant treatment: HICON trial | Q33942343 | ||
| SCOPE1: a randomised phase II/III multicentre clinical trial of definitive chemoradiation, with or without cetuximab, in carcinoma of the oesophagus | Q34061012 | ||
| Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. | Q34488692 | ||
| Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction | Q34603020 | ||
| Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial | Q34627996 | ||
| A meta-analysis of D1 versus D2 lymph node dissection. | Q34634079 | ||
| Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial | Q34634440 | ||
| Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial | Q34634936 | ||
| Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection | Q34638268 | ||
| (18)F-FDG PET-guided salvage neoadjuvant radiochemotherapy of adenocarcinoma of the esophagogastric junction: the MUNICON II trial. | Q51547649 | ||
| Phase 3 trial of postoperative chemotherapy alone versus chemoradiation therapy in stage III-IV gastric cancer treated with R0 gastrectomy and D2 lymph node dissection. | Q53361535 | ||
| Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction. | Q53520806 | ||
| Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer | Q57259796 | ||
| A comparison of multimodal therapy and surgery for esophageal adenocarcinoma | Q71164736 | ||
| Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer | Q77738544 | ||
| Adenocarcinoma of the esophagogastric junction: surgical therapy based on 1602 consecutive resected patients | Q79214559 | ||
| Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer | Q80807888 | ||
| Preinvasive neoplasia in the stomach: diagnosis and treatment | Q81159187 | ||
| Gastric cancer: Nagoya is not New York | Q82087857 | ||
| Perioperative docetaxel, cisplatin, and 5-fluorouracil (DCF) for locally advanced esophageal and gastric adenocarcinoma: a multicenter phase II trial | Q82265485 | ||
| Extended follow-up after extended lymphadenectomy for gastric cancer: was it worth the wait? | Q84088565 | ||
| Gastric cancer--an enigmatic and heterogeneous disease | Q84156232 | ||
| Gastroesophageal cancer: focus on epidemiology, classification, and staging | Q34655807 | ||
| Adjuvant chemoradiotherapy after d2-lymphadenectomy for gastric cancer: the role of n-ratio in patient selection. results of a single cancer center | Q36524081 | ||
| Treatment of thoracic esophageal carcinoma invading adjacent structures | Q36794837 | ||
| Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial | Q36950483 | ||
| The Value of PET Imaging in Patients with Localized Gastroesophageal Cancer | Q37076617 | ||
| Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. | Q37449181 | ||
| Trastuzumab for gastric cancer | Q37633540 | ||
| Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis | Q37742318 | ||
| Transhiatal versus transthoracic esophagectomy for esophageal cancer | Q37779057 | ||
| Oesophagogastric junction adenocarcinoma: which therapeutic approach? | Q37812516 | ||
| Molecular profiling of cancer--the future of personalized cancer medicine: a primer on cancer biology and the tools necessary to bring molecular testing to the clinic | Q37855225 | ||
| Endotherapy for Barrett's esophagus | Q38001289 | ||
| Phase II study of neoadjuvant therapy with docetaxel, cisplatin, panitumumab, and radiation therapy followed by surgery in patients with locally advanced adenocarcinoma of the distal esophagus (ACOSOG Z4051). | Q38435643 | ||
| Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. | Q39737918 | ||
| Integration of targeted agents in the neo-adjuvant treatment of gastro-esophageal cancers | Q39933959 | ||
| PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial | Q40184245 | ||
| Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer | Q43273409 | ||
| Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer | Q43620764 | ||
| Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging | Q43641822 | ||
| Adjuvant therapy for gastric cancer: revisiting the past to clarify the future. | Q43777300 | ||
| Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial | Q44017893 | ||
| Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. | Q44022873 | ||
| Pathological complete remission in patients with oesophagogastric cancer receiving preoperative 5-fluorouracil, oxaliplatin and docetaxel | Q44143001 | ||
| An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach | Q46649725 | ||
| Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. | Q46675470 | ||
| Post-treatment endoscopic biopsy is a poor-predictor of pathologic response in patients undergoing chemoradiation therapy for esophageal cancer | Q46682111 | ||
| P275 | copyright license | Creative Commons Attribution 2.0 Generic | Q19125117 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | adenocarcinoma | Q356033 |
| stomach neoplasm | Q4335552 | ||
| gastroesophageal cancer | Q61913382 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 66 | |
| P577 | publication date | 2013-09-05 | |
| P1433 | published in | Journal of Hematology & Oncology | Q15724593 |
| P1476 | title | Perioperative therapy for locally advanced gastroesophageal cancer: current controversies and consensus of care | |
| P478 | volume | 6 |
| Q37734452 | "Targeted" Chemotherapy for Esophageal Cancer |
| Q37225659 | Antitumor activity and inhibitory effects on cancer stem cell-like properties of Adeno-associated virus (AAV) -mediated Bmi-1 interference driven by Bmi-1 promoter for gastric cancer |
| Q39006844 | Basis for molecular diagnostics and immunotherapy for esophageal cancer. |
| Q53496643 | Influence of Different Neoadjuvant Chemotherapy Regimens on Response, Prognosis, and Complication Rate in Patients with Esophagogastric Adenocarcinoma. |
| Q26992272 | Next-generation clinical trials: Novel strategies to address the challenge of tumor molecular heterogeneity |
| Q39171565 | Novel Targeted Therapies for Esophagogastric Cancer |
| Q35346910 | Perioperative chemotherapy in gastroesophageal cancer. A retrospective monocenter evaluation of 42 cases |
| Q38824375 | Potentially Curable Cancers of the Esophagus and Stomach. |
| Q38684349 | Update on Gastroesophageal Adenocarcinoma Targeted Therapies |
Search more.